Secondary Logo

Journal Logo

Covid 19

Prevalence of COVID-19-like symptoms in Italy and Lombardy, March–April 2020, and their implications on cancer prevention, diagnosis and management

Negri, Evaa; Scarpino, Vilmab; La Vecchia, Carloc

Author Information
European Journal of Cancer Prevention: March 2021 - Volume 30 - Issue 2 - p 123-125
doi: 10.1097/CEJ.0000000000000604
  • Free


Several thousand patients infected with coronavirus disease-2019 (COVID-19) were projected in Italy by mid-March (Remuzzi and Remuzzi, 2020), and registered COVID-19 cases were over 110 000 by the end of March (Boccia et al., 2020).

Italy, and its largest region, Lombardy (with 10 million inhabitants), have been also subsequently heavily hit by the COVID-19 epidemic. According to official data (Protezione Civile, 2020), up to 21 April 183 857 cases and 24 648 deaths were registered in Italy. Corresponding figures for Lombardy were over 67 931 cases and over 12 579 deaths.

The COVID pandemic has substantial health implications besides its direct effects on population morbidity and mortality (Rosenbaum, 2020). Cancer screening, diagnosis and management have been heavily affected by the current pandemic, and it is, therefore, important to provide figures on Covid cases and deaths, in order to provide a perspective for the evolution of the pandemic and its potential implications on cancer patients (Nelson, 2020; Vrdoljak et al., 2020). Each year, in Italy, about 180 000 cancer deaths are registered, corresponding to over 350 000 incident and 2 million prevalent cases (Santucci et al., 2020). These figures have to be put in perspective with the current Covid cases, deaths and hospital burden.

The real number of Covid cases is, however, undefined, and in Italy registered cases include essentially hospital admissions, plus a small number of positive subjects from nonorganized PCR tampons.

To obtain an estimate of possible number of cases, we included a series of questions on COVID-19-related symptoms (including fever, headache, cold, cough, gastrointestinal disorders-plus, separately, fever over 38.5°C), in two weekly national surveys routinely conducted by BVA-Doxa. The first survey was conducted on 27–30 March, and based on a sample of 1000 individuals, representative of the general Italian population aged 18–85 in terms of sex, age, geographic area and socioeconomic status. Of these, 169 subjects were resident in Lombardy. The second survey was conducted on 3–7 April, using a different sample identified with the same criteria also included 1000 subjects, 184 from Lombardy. Thus, the two waves combined cover the period 7 March–7 April. The data were collected using computer-assisted web interviews and related to the 3-week preceding data collection. Confidence intervals of percentage estimates were based on the binomial distribution. We also computed the odds ratios (ORs), and the corresponding 95% confidence intervals (CIs) of reporting Covid-19-like symptoms, including terms for sex, age, smoking, education, wave of interview, and area of residence.

The key findings are given in Table 1. In Italy, 14.2% of subjects reported some COVID-19-like symptoms, and 1.3% fever over 38.5°C over the last 3 weeks. Corresponding figures for Lombardy were 19.6% for any symptom, and 2.3% for fever over 38.5°C. Both in Italy and in Lombardy, the proportion of subjects reporting COVID-19-like symptoms was higher in women than in men, at younger age than in middle age and the elderly, in smokers than in nonsmokers, and in subjects with higher education. For age and smoking, the differences were significant.

Table 1 - Prevalence (%) and 95% confidence intervals of Covid19-like symptoms in the last three weeks in a representative sample of the Italian population. BVA-Doxa, Italian national surveys, 27–30 March and 3–7 April 2020
Italy (N,%) N = 2000 Lombardy (%) N = 353
N (yes/no) % Yes N (yes/no) % Yes
Covid19-like symptoms 283/1717 14.2 (12.6–15.7) 69/284 19.6 (12.8–25.0)
Fever >38.5°C 26/1974 1.3 (0.8–1.8) 8/345 2.3 (0.9–4.42)
Any symptom by strata
 Men 133/828 13.8 30/142 17.4
 Women 150/889 14.4 39/142 21.6
P = 0.70 P = 0.33
 18–44 148/624 19.2 40/91 30.5
 45–64 79/610 11.5 15/115 11.5
 65–85 56/483 10.4 14/78 15.2
P-trend < 0.0001 P-trend = 0.0017
 No 172/1218 12.4 41/210 16.3
 Yes 111/499 18.2 28/74 27.5
P = 0.0006 P = 0.02
Educational level
 Middle school or less 36/231 13.5 6/40 13.0
 High school 135/894 13.1 37/150 19.8
 University 112/592 15.9 26/94 21.7
P-trend = 0.17 P-trend = 0.25
Wave of interview
 27–31 March 144/856 14.4 31/138 18.3
 3–7 April 139/861 13.9 38/146 20.7
P = 0.75 P = 0.59

Table 2 gives the corresponding multivariate ORS. These were 2.0 (95% CI, 1.5–2.8) for the young vs. the elderly, 1.6 (95% CI, 1.2–2.1) for smokers vs. nonsmokers, and 1.7 (95% CI, 1.2–2.3) for Lombardy ves other Italian regions.

Table 2 - Prevalence odds ratio and 95% confidence intervals of Covid-19-like symptoms in the last 3 weeks in a representative sample of the Italian population. BVA-Doxa, Italian national survey 27–30 March and 3–7 April 2020
ORa (95% CI)
 Men 1 (ref)
 Women 1.03 (0.80–1.34)
 18–44 2.02 (1.45–2.82)
 45–64 1.10 (0.76–1.59)
 65–85 1 (ref)
 No 1 (ref)
 Yes 1.62 (1.24–2.11)
Educational level
 Middle school or less 1 (ref)
 High school 0.97 (0.65–1.44)
 University 1.17 (0.77–1.77)
Wave of interview
 27–31 March 1 (ref)
 3–7 April 0.94 (0.73–1.21)
Area of residence
 Lombardy 1.7 (1.24–2.28)
 Other 1 (ref)
OR, odds ratio.
aEstimated from a logistic model including all the terms above.

At least part of the symptoms reported is not COVID-19 related. Although the annual flu season had ended by mid-March – and was particularly moderate the last winter, part of the symptoms reported may well be related to other, nonspecific (viral) conditions. It is possible; however, that a considerable proportion of symptoms – and most of fever over 38.5°C in March and early April – were due to COVID-19. Even assuming that only about half of reported symptoms were due to COVID-19, over 7% of the population in Italy and 10% in Lombardy would have been affected by COVID-19 in the weeks covered by data collection only. This would correspond to at least 5 million subjects affected in Italy, and 1 million in Lombardy alone, a figure that can be doubled assuming that most COVID-19-like symptoms are indeed COVID-19 related. The information was restricted to a 2-week period, and additional subjects likely had been affected before 20 March. In addition, an undefined proportion of the population has been affected by totally asymptomatic or minimally symptomatic, COVID-19, and was not reported in our surveys.

While the key limitation of the surveys considered are their subjective, self-reporting of symptoms, they have the strength of being included in a routinely weekly conducted, validated survey, of being reasonably large, and representative of the general population of Italy and Lombardy.

The larger proportion of symptoms at younger age likely reflects more active social interactions in this age group.

These data indicate therefore that – even ignoring asymptomatic cases – the COVID-19 epidemic may well have affected a substantial proportion of the Italian population by early April, certainly at least one order of magnitude larger, and possibly up to two orders of magnitude larger, than the registered cases.

Still, these estimates remain far from those required to reach adequate natural immunity on a population level and indicate therefore that the COVID pandemic is going to persist in Italy at least for the next few months.

This would, therefore, imply unique challenges to the diagnosis and management of other diseases, including cancer.


The survey was conducted and supported by BVA-Doxa with internal funding.

Conflicts of interest

There are no conflicts of interest.


Boccia S, Ricciardi W, Ioannidis JPA. What other countries can learn from Italy during the COVID-19 pandemic. JAMA Intern Med. 2020. doi: 10.1001/jamainternmed.2020.1447.
Nelson B. Covid-19 is shattering US cancer care. BMJ. 2020: 369. doi: 10.1136/bmj.m1544.
    Protezione Civile 2020. (accessed 22 April 2020).
      Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020: 395:1225–1228.
      Rosenbaum L. The untold toll – the pandemic’s effects on patients without Covid-19. N Engl J Med. 2020.
      Santucci C, Carioli G, Bettuccio P, Malvezzi M, Boffetta P, Negri E, et al. 2020. Progress in cancer mortality, incidence, and survival: a global overview. Eur J Cancer Preve: in press.
      Vrdoljak E, Sullivan R, Lawler M. 2020. Cancer and COVID-19; how do we manage cancer optimally through a public health crisis? Eur J Cancer: in press.

      coronavirus disease-2019; cancer prevention; cancer treatment; prevalence

      Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.